Targeting IRAK1 as a therapeutic approach for Myelodysplastic Syndrome

Myelodysplastic Syndromes (MDS) arise from a defective hematopoietic stem/progenitor cell. Consequently, there is an urgent need to develop targeted therapies capable of eliminating the MDS-initiating clones. We identified that IRAK1, an immune modulating kinase, is overexpressed and hyperactivated...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rhyasen, Garrett W., Bolanos, Lyndsey, Fang, Jing, Jerez, Andres, Wunderlich, Mark, Rigolino, Carmela, Mathews, Lesley, Ferrer, Marc, Southall, Noel, Guha, Rajarshi, Keller, Jonathan, Thomas, Craig, Beverly, Levi J., Cortelezzi, Agostino, Oliva, Esther N., Cuzzola, Maria, Maciejewski, Jaroslaw P., Mulloy, James C., Starczynowski, Daniel T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3711103/
https://ncbi.nlm.nih.gov/pubmed/23845443
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2013.05.006
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak